123910-87-2

Upstream product

• 5390-04-5 pent-1-yn-5-ol 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 619-44-3 methyl 4-iodobenzoate 

Downstream Products

• 1346424-46-1 4-(5-Hydroxypent-1-yn-1-yl)benzoic acid 
• 126295-75-8 4-(6,6-Dicyano-4-diethoxymethyl-hex-5-enyl)-benzoic acid methyl ester 
• 123910-82-7 Methyl 4-<3-(2-Amino-3,4-dihydro-4-oxo-5-deazapteridin-6-yl)propyl>benzoate 
• 123910-92-9 4-<3-(2-Amino-3,4-dihydro-4-oxo-5-deazapteridin-6-yl)propyl>benzoic acid 
• 123910-85-0 Methyl 4-<6,6-dicyano-4-(ethoxymethylidene)-5-hexenyl>benzoate 
• 126295-73-6 Methyl 4-(6,6-dicyano-5-hexenyl)benzoate 
• 123910-90-7 4-(4'-Carbomethoxyphenyl)valeraldehyde 
• 123910-89-4 methyl 4-(5-hydroxypent-1-yl)benzoate 

Relevant academic research and scientific papers

Palladium-Catalyzed Synthesis of Tricyclic Indoles via a N-S Bond Cleavage Strategy

In palladium/norbornene (Pd/NBE) chemistry, the "ortho effect"has been proven to be a key factor in the process of β-carbon elimination to extrude NBE. Herein, we found that the o-iodoaniline protected by a p-methoxybenzenesulfonyl group can recover the "

Compound as protein degradation agent and preparation method and medical application thereof

The invention discloses a compound serving as a protein degrading agent and a preparation method and medical application thereof, and particularly discloses a compound represented by the formula (I) and a pharmaceutically acceptable salt thereof, and the

Compounds and Their Use in Treating Cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

Exploration of a Au(i)-mediated three-component reaction for the synthesis of DNA-tagged highly substituted spiroheterocycles

We demonstrate a Au(i)-mediated three-component reaction to DNA-tagged highly substituted 6-oxa-1,2-diazaspiro[4.4]nonanes from either DNA-coupled aldehydes, hydrazides, or alkynols. The choice of the starting material coupled to the DNA tag was critial for the purity of the product as the DNA-aldehyde conjugate yielded the purest products, whereas the alkynol- and hydrazide conjugates returned complex product mixtures. The reaction was compatible with thymine-, cytosine-, and, surprisingly, with adenine-DNA, while guanine-containing DNA strands were degraded under the reaction conditions.

Direct synthesis of macrodiolides via hafnium(iv) catalysis

Efficient direct synthesis of macrodiolides via catalysis using Hf(OTf)4 is possible in high yields, forming water as the sole by-product. The first protocol for the direct synthesis of macrodiolides from equimolar mixtures of diols and dicarbo

BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS

This invention provides compounds of the formula: wherein X is wherein R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring and all other variables are as defined herein, their use in pulmonary inflammation or bronchoconstriction therapy and compositions comprising and processes for preparing the same are provided.

Process for the preparation of fused pyridine compounds

Pyrido[2,3-d]pyrimidine compounds are prepared through the reaction of 2,4-diamino-6(1H)-pyrimidone and an activated derivative of a dialdehyde. A typical embodiment utilizes the dinitrile.

L-glutamic acid derivatives

Pyrimidin-5-yl derivatives of L-glutamic acid are anti-neoplastic agents. A typical embodiment is N-(4-[4-(2,4-diamino-6-hydroxypyrimidin-5-yl)-butyl]-benzoyl)-L-glutamic acid.